Publisher's Note

Recently published articles about Publisher's Note

Publisher's Note

A New Decade

January 28, 2020

In this publisher's note, Dr John Shelton reflects on JCP's progress over the last 10 years.

John S. Shelton

Publisher's Note

Celebrating JCP's 80th Year

January 8, 2019

John S. Shelton, Publisher, takes a look back at 80 years of JCP and a look forward toward its future.

John S. Shelton

Publisher's Note

PCC: 20 Years Old and Growing

March 1, 2018

John S. Shelton

Publisher's Note

Thirty Great Years

December 27, 2017

John S. Shelton

Publisher's Note

Introducing JCP Weekly

May 24, 2017

John S. Shelton

Publisher's Note

JCP: A Look Back, and a Look Forward

March 29, 2017

John S. Shelton

Recent JCP Articles on Publisher's Note

The Goldilocks Problem: Balancing Internal Validity with Generalizability in Clinical Trials

Commentary

The Goldilocks Problem: Balancing Internal Validity with Generalizability in Clinical Trials

November 26, 2025

The author discusses a recent analysis by Zimmerman and Snyder focusing on the generalizability of PTSD treatment trials.

Lori L. Davis

Lack of Generalizability of PTSD Treatment Trials: The Recent Brexpiprazole-Sertraline Trials as an Example

Original Research

Lack of Generalizability of PTSD Treatment Trials: The Recent Brexpiprazole-Sertraline Trials as an Example

November 26, 2025

In an outpatient psychiatry sample, nearly 95% of patients who want treatment for PTSD would not have qualified for the trials of brexpiprazole-sertraline for PTSD.

Mark Zimmerman, Matthew Snyder

MAOI Antidepressants: A History Being Rewritten

Commentary

MAOI Antidepressants: A History Being Rewritten

November 26, 2025

Members of the International MAOI Expert Group discuss historical use of MAOIs, consider their efficacy and safety, and underscore the importance of reassessing their place in treatment algorithms.

Vincent Van den Eynde, Chittaranjan Andrade, Michael Berk, et al

Recent PCC Articles on Publisher's Note

Benzodiazepine-Induced Neurologic Dysfunction

Case Report

Benzodiazepine-Induced Neurologic Dysfunction

November 27, 2025

This case illustrates how benzodiazepine-induced neurologic dysfunction and benzodiazepine use disorder can coexist, emphasizing the importance of distinguishing between them to guide diagnosis and management.

Danielle M. Krohn, Alëna A. Balasanova

From Varenicline to Neuroleptic Malignant Syndrome

Case Report

From Varenicline to Neuroleptic Malignant Syndrome

November 27, 2025

This case highlights the complexity of diagnosing atypical neuroleptic malignant syndrome in high-risk individuals after sudden cessation of varenicline and cigarette smoking.

Monica A. Nava Frenier, Maxwell F. Lydiatt

Comorbidities Obscure Autism Diagnosis

Case Report

Comorbidities Obscure Autism Diagnosis

November 25, 2025

A 14-year-old boy with longstanding psychotic illness, posttraumatic stress from adverse social experiences, and suicidality presented for neuropsychiatric assessment.

Michael R. Capawana

Featured Publisher's Note Research

Can a Superhero Make Us Kinder?

news

Can a Superhero Make Us Kinder?

November 26, 2025

A brief subway experiment in Italy found that a superhero’s unexpected presence nudged riders to act more kindly.

Sustained Symptom Improvement Across Domains With Long-Term Xanomeline–Trospium Treatment

news

Sustained Symptom Improvement Across Domains With Long-Term Xanomeline–Trospium Treatment

November 25, 2025

One year of xanomeline–trospium treatment sustained improvements across all schizophrenia symptom domains in EMERGENT-4. Patients switching from placebo caught up within just 4 weeks.

Impact of Dose and Titration Speed on the Tolerability of Xanomeline–Trospium in Schizophrenia

news

Impact of Dose and Titration Speed on the Tolerability of Xanomeline–Trospium in Schizophrenia

November 25, 2025

Faster xanomeline–trospium titration to 125 mg/30 mg twice daily improved tolerability versus slower dosing, challenging start low go slow assumptions.